Speaker: Dr. Paolo Ghia, Full Professor, Medical Oncology
Director, Strategic Research Program on CLL
Deputy chairman, Experimental Oncology Division
Head, B-Cell Neoplasia Unit
Università Vita-Salute San Raffaele, Milano, Italy
IRCCS Ospedale San Raffaele, Milano, Italy

Description: Management of patients affected by CLL is becoming more complicated with the availability of novel treatments as monotherapy and/or in combination. The possibility of utilizing therapeutic options in a continuous fashion or with a fixed-duration schedule allows more flexibility to the caring physician to adapt to the patient’s preferences but also involves the need of carefully evaluating the genetic features and the overall fitness profile of each single individuals in order to obtain the most durable control of the disease at the lowest risk of adverse events.

At the end of this session, participants will be able to:
-Identify the patients with CLL at high risk of progression after immuno-chemotherapy
-define the define the subgroups of patients with CLL who will benefit from either continuous or fixed-duration treatments

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours.

Conflict of Interest: Consultancy – AstraZeneca, AbbVie, Biegene, BMS, Janssen, Lilly/Loxo Oncology, MDS, Roche. Research funding and/or clinical trials: AstraZeneca, AbbVie, Biegene, BMS, Janssen, Lilly/Loxo Oncology, MDS, Roche

Target Audience: Hematologists, Medical Oncologists, Residents

This webinar is offered free of charge to CHS Members.